In a latest development, Hyderabad-based drug developer Suven Life Sciences has informed that its molecule for Alzheimer's disease will soon enter phase two trials.

According to sources, the phase two trials will cost the company $20 million. The company is presently in the process of raising funds for the trials through a combination of debt, equity and strategic partner.

Last week, the company announced that more than half-a-dozen companies have shown interest in partnering the company for developing 'SUVN 502' molecule.

Red Fort Capital, a leading international real estate private equity fund, intends to invest Rs 3,200 crore by next year to cash in on the liquidity crunch in the real estate sector. 

The real estate focused PE fund has planned to pump in Rs 3,200 crore in the next one year to pick up an average 50% stake each in 10-12 projects located in various cities. 

The company presently is in talks with nearly 10 developers in various cities across country, which includes National Capital Region (NCR), Mumbai, Bangalore, Kolkata, Chennai, Pune and Hyderabad.